Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Keratosis, Actinic 1

Interventions

pembrolizumab 64Carboplatin 63Paclitaxel 54Magnetic Resonance Spectroscopy 45Specimen Handling 43Cisplatin 43Gemcitabine 35Bevacizumab 31Docetaxel 30Doxorubicin 29Leucovorin 28Fluorouracil 27Dexamethasone 27Cyclophosphamide 26Pemetrexed 25Radiation 23Oxaliplatin 23Radiotherapy 22Etoposide 22durvalumab 21Nivolumab 21Letrozole 21Vincristine 20Rituximab 20Irinotecan 20Taxes 19Prednisone 19Capecitabine 19Lenalidomide 18130-nm albumin-bound paclitaxel 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × BF-200 ALA × 30 days × Clear all
NCT05662202 2026-05-22

Study to Evaluate the Safety, Tolerability and Efficacy of BF-200 ALA (Ameluz®) in the Field-directed Treatment of Actinic Keratosis (AK) on the Extremities and Neck/Trunk With Photodynamic Therapy (PDT) Using a RhodoLED Lamp

Biofrontera Inc.

Phase 3 Active not recruiting
172 enrolled
Dermatologic

Keratosis, Actinic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡